Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran

  • Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 were on inclisiran) 1
     
  • New post-hoc analysis demonstrates 99% of patients treated with inclisiran showed placebo-adjusted reduction in low-density lipoprotein cholesterol (LDL-C) of ≥30% with a mean reduction of 54.1% from baseline (observed values)2
     
  • 88% of inclisiran-treated patients achieved LDL-C …
/by